Cytoskeletal drugs

Cytoskeletal drugs are small molecules that interact with the cytoskeletal proteins actin or tubulin. These drugs affect the cytoskeleton in one of three main ways: stabilizing cytoskeletal filaments, preventing the polymerization of protein monomers, or promoting the depolymerization of existing filaments.

Drugs that target microtubules, such as paclitaxel (taxol), are often used in chemotherapy for the treatment of cancer. In contrast, drugs that target actin have limited clinical use due to severe off-target effects but remain valuable tools in cellular research.

Mechanisms of action

Cytoskeletal drugs can interfere with the normal dynamics of actin filaments and microtubules through several mechanisms.

Stabilization

Some drugs bind to and stabilize existing cytoskeletal polymers, preventing their depolymerization. Notable examples include taxol, which stabilizes microtubules, and phalloidin, which stabilizes actin filaments.

Inhibition of polymerization

Other drugs bind to free monomers and prevent them from polymerizing. Cytochalasin D, for instance, binds to actin monomers, while colchicine prevents the polymerization of microtubules.

Promotion of depolymerization

Certain drugs enhance the disassembly of already formed polymers. Demecolcine acts by promoting the depolymerization of microtubules.

Some drugs exhibit multiple effects. Latrunculin, for example, both prevents actin polymerization and enhances the rate of filament depolymerization.

Microtubule-targeting drugs

Drugs that target microtubules are frequently used in the clinic, primarily as anticancer agents in chemotherapy. By disrupting microtubule dynamics, these drugs interfere with mitosis in rapidly dividing cancer cells. Examples include:

Paclitaxel (taxol), which stabilizes microtubules and halts mitosis.
Vinblastine, nocodazole, and colchicine, which prevent the polymerization of tubulin monomers.
Demecolcine, which actively depolymerizes formed microtubules.
Rotenone, which prevents polymerization and is used as a pesticide.

Actin-targeting drugs

The clinical use of actin-targeting drugs in animals is limited by a lack of specificity, as they cannot distinguish between different forms of actin (e.g., muscle vs. cytoskeletal). This leads to unacceptable off-target effects. However, these compounds are useful research tools for understanding the cell's internal machinery. For example, phalloidin conjugated with a fluorescent probe can be used to visualize actin filaments in fixed cell samples.

Depolymerizing agents

Cytochalasin D and latrunculin both promote the depolymerization of actin filaments but through different mechanisms. When added to live cells, they disassemble the actin cytoskeleton and inhibit cell movements like locomotion.

Cytochalasin D, a fungal alkaloid, binds to the (+) end of F-actin and blocks the addition of new actin subunits.
Latrunculin, a toxin secreted by sponges, binds to and sequesters G-actin monomers, preventing their addition to a filament end.

Stabilizing agents

In contrast to the above, other toxins stabilize actin filaments.

Jasplakinolide, a toxin from sponges, binds to and stabilizes actin dimers by enhancing nucleation. This lowers the critical concentration required to form filaments.
Phalloidin, a phallotoxin from the Amanita phalloides mushroom, prevents filament depolymerization by binding between F-actin subunits and locking them together. This paralyzes the cell, leading to cell death.

Toxicity of phallotoxins

Phallotoxins are isolated from A. phalloides, commonly known as the "death cap" mushroom, which has been involved in fatal cases of mushroom poisoning. Ingestion of the mushroom most commonly affects the liver and kidneys, causing symptoms that can include jaundice and seizures, ultimately resulting in death within hours. Three classes of toxins are found in A. phalloides: amatoxins, phallotoxins, and virotoxins. Like phallotoxins, virotoxins also interact with actin to prevent filament depolymerization, disrupting cytoskeletal function and paralyzing susceptible cells.

Summary table

The following table summarizes the targets and effects of several common cytoskeletal drugs.

References